Celltrion Eyes Remsima SC Launches In Canada And Australia
Company On Track To Launch At Least One Biosimilar Every Year By 2030
• By Akriti Seth
Celltrion is focused on launching subcutaneous infliximab in Canada and Australia, and adalimumab in Europe • Source: Alamy